OptiNose, Inc. (NASDAQ: OPTN) was founded in 2000 and is headquartered in Yardley, Pennsylvania, USA, with 102 full-time employees (12/31/2018). It is a professional pharmaceutical company focusing on ENT and allergy medicines Development and commercialization.
OptiNose, Inc. (OPTN):
Per Djupesland, as an otolaryngologist and an expert in the treatment of sinus diseases, as well as the co-founder and Chief Scientific Officer (CSO) of OptiNose, has a deep understanding of the limitations of existing nasal cavity treatments-the same patient repeatedly comes Going to the clinic, suffering, unable to find a lasting treatment plan, and in many cases undergoing one or more operations. Per Djupesland, MD has deeply studied the nasal cavity dynamics and the function of the nasal trachea. He found the solution through anatomy-the patient’s own breathing is the solution. .
Dr. Djupesland devised a method of applying natural human mechanics to push the medicine into the nasal cavity more effectively and continuously than other methods. This insight led to the design of the first drug delivery device model and the technological concept now constructed by Optinose. With the encouragement of his wife Helena and the help of business experience, they submitted their first patent, established Optinose in 2000, and began to use this concept to raise funds needed to support the development of new products.
In January 2014, Optinose and Avanir submitted a new drug application to the U.S. Food and Drug Administration (FDA) for the company’s first product, using the Optinose device to administer sumatriptan (sumatriptan) to treat migraine. The application (now approved) includes clinical data showing that Optinose uses very low doses of the drug to significantly improve migraine symptoms within 30 minutes. To help doctors and patients understand the effects of this new method, Optinose conducted another clinical trial to directly compare its new migraine treatment with the most commonly used migraine drugs. The results of the test have now been announced. Optinose has conducted another phase III trial of Optinose device worldwide, combining fluticasone, a topical steroid used to treat patients with chronic rhinitis (CNID). It is estimated that CNID affects more than 40 million people in the United States alone. And all this is just the beginning.
On September 18, 2017, the US Food and Drug Administration (FDA) approved Optinose’s New Drug Application (NDA)-XHANCE for the treatment of nasal polyps in patients 18 years of age or older. The company expects to launch XHANCE products to treat nasal polyps in the second quarter of 2018. The dedicated sales team includes a team of doctors composed of approximately 15,000 professional prescription pharmacists in the United States. Optinose also plans to start additional clinical trials on CHANCE in the second half of 2018, seeking follow-up indications for the treatment of chronic sinusitis, in order to expand the company’s market opportunities.
OptiNose, Inc. (OPTN) investment:
OptiNose, Inc. (NASDAQ: OPTN) submitted its IPO prospectus on 9/18/2017 and listed on Nasdaq on 10/13/2017 with an issue price of US$15.006.00. It issued 7.5 million shares and raised US$120 million. , Stock code: OPTN.